Ralph Schiess
Fortuna: 190 $ al 31/05/2026
Fortuna: 190 $ al 31/05/2026
Ralph Schiess was the founder of Proteomedix AG, founded in 2010, and held the title of Chief Executive Officer from 2023 to 2025.
Former job includes Chief Executive & Science Officer at Onconetix, Inc. from 2024 to 2025.
Education includes graduate degree from the University of Zurich and doctorate from the Swiss Federal Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ONCONETIX INC 0,01 % | 13/03/2026 | 158 ( 0,01 % ) | 190 $ | 31/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Proteomedix AG
Proteomedix AG BiotechnologyHealth Technology Operates as a private, commercial-stage diagnostics oncology company | Director Ejecutivo | 31/05/2025 |
| ONCONETIX, INC. | Director Ejecutivo | 24/02/2025 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
University of Zurich
University of Zurich Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swiss Federal Institute of Technology
Swiss Federal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Proteomedix AG
Proteomedix AG BiotechnologyHealth Technology Operates as a private, commercial-stage diagnostics oncology company | Health Technology |
Onconetix, Inc.
Onconetix, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology drugs and diagnostic test for cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.